These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 34391173)

  • 21. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial simulation to evaluate tenofovir disoproxil fumarate/emtricitabine HIV pre-exposure prophylaxis dosing during pregnancy.
    Scott RK; Yu Y; Marzinke MA; Coleman JS; Hendrix CW; Bies R
    Front Reprod Health; 2023; 5():1224580. PubMed ID: 37830105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
    Anderson PL; Glidden DV; Bushman LR; Heneine W; García-Lerma JG
    J Antimicrob Chemother; 2014 Sep; 69(9):2470-6. PubMed ID: 24862094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
    Cattani VB; Jalil EM; Eksterman L; Torres T; Cardoso SW; Castro CRV; Monteiro L; Wilson E; Bushman L; Anderson P; Veloso VG; Grinsztejn B; Estrela R;
    J Antimicrob Chemother; 2022 Sep; 77(10):2729-2736. PubMed ID: 35815666
    [TBL] [Abstract][Full Text] [Related]  

  • 25. On-Demand Oral Pre-exposure Prophylaxis with Tenofovir/Emtricitabine: What Every Clinician Needs to Know.
    Saberi P; Scott HM
    J Gen Intern Med; 2020 Apr; 35(4):1285-1288. PubMed ID: 31965523
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.
    Mills A; Crofoot G; Ortiz R; Rashbaum B; Towner W; Ward D; Brinson C; Kulkarni R; Garner W; Ebrahimi R; Cao H; Cheng A; Szwarcberg J
    HIV Clin Trials; 2014; 15(2):51-6. PubMed ID: 24710918
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
    Anderson PL; Liu AY; Castillo-Mancilla JR; Gardner EM; Seifert SM; McHugh C; Wagner T; Campbell K; Morrow M; Ibrahim M; Buchbinder S; Bushman LR; Kiser JJ; MaWhinney S
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038282
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
    Grant RM; Mannheimer S; Hughes JP; Hirsch-Moverman Y; Loquere A; Chitwarakorn A; Curlin ME; Li M; Amico KR; Hendrix CW; Anderson PL; Dye BJ; Marzinke MA; Piwowar-Manning E; McKinstry L; Elharrar V; Stirratt M; Rooney JF; Eshleman SH; McNicholl JM; van Griensven F; Holtz TH
    Clin Infect Dis; 2018 May; 66(11):1712-1721. PubMed ID: 29420695
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
    Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
    Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, phase 2 evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection.
    Cohen C; Elion R; Ruane P; Shamblaw D; DeJesus E; Rashbaum B; Chuck SL; Yale K; Liu HC; Warren DR; Ramanathan S; Kearney BP
    AIDS; 2011 Mar; 25(6):F7-12. PubMed ID: 21412057
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
    DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
    Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Daily or on-demand oral tenofovir disoproxil fumarate/emtricitabine for HIV pre-exposure prophylaxis: experience from a hospital-based clinic in France.
    Noret M; Balavoine S; Pintado C; Siguier M; Brun A; Bauer R; Loze B; Leplatois A; Aslan A; Moudachirou K; Delaugerre C; Rozenbaum W; Molina JM
    AIDS; 2018 Sep; 32(15):2161-2169. PubMed ID: 30212403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.
    Cahn P; Kaplan R; Sax PE; Squires K; Molina JM; Avihingsanon A; Ratanasuwan W; Rojas E; Rassool M; Bloch M; Vandekerckhove L; Ruane P; Yazdanpanah Y; Katlama C; Xu X; Rodgers A; East L; Wenning L; Rawlins S; Homony B; Sklar P; Nguyen BY; Leavitt R; Teppler H;
    Lancet HIV; 2017 Nov; 4(11):e486-e494. PubMed ID: 28918877
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Men who have sex with men more often chose daily than event-driven use of pre-exposure prophylaxis: baseline analysis of a demonstration study in Amsterdam.
    Hoornenborg E; Achterbergh RC; van der Loeff MFS; Davidovich U; van der Helm JJ; Hogewoning A; van Duijnhoven YT; Sonder GJ; de Vries HJ; Prins M;
    J Int AIDS Soc; 2018 Mar; 21(3):e25105. PubMed ID: 29603900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073.
    Zhang Y; Clarke W; Marzinke MA; Piwowar-Manning E; Beauchamp G; Breaud A; Hendrix CW; Cloherty GA; Emel L; Rose S; Hightow-Weidman L; Siegel M; Shoptaw S; Fields SD; Wheeler D; Eshleman SH
    Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28438932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maximizing the Benefits of HIV Preexposure Prophylaxis.
    Buchbinder SP
    Top Antivir Med; 2018 Apr; 25(4):138-142. PubMed ID: 29689539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
    Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A
    AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preexposure Prophylaxis for the Prevention of HIV Infection: US Preventive Services Task Force Recommendation Statement.
    ; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Curry SJ; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Simon MA; Tseng CW; Wong JB
    JAMA; 2019 Jun; 321(22):2203-2213. PubMed ID: 31184747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.